AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousPeripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationStem CellsTransplantation, HomologousHematopoietic Stem Cell MobilizationBone Marrow TransplantationStem Cell TransplantationTransplantation ConditioningHematopoietic Stem CellsLeukapheresisGranulocyte Colony-Stimulating FactorAntigens, CD34Multiple MyelomaMelphalanGraft SurvivalLiver TransplantationCord Blood Stem Cell TransplantationCombined Modality TherapyGraft vs Host DiseaseBlood Component RemovalTreatment OutcomeHematologic NeoplasmsCyclophosphamideLymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsKidney TransplantationRecurrenceBusulfanSalvage TherapyBone Marrow PurgingWhole-Body IrradiationRemission InductionEmbryonic Stem CellsEtoposideAdult Stem CellsCell TransplantationHematopoiesisCell DifferentiationTissue DonorsCells, CulturedBlood Cell CountTime FactorsBlood CellsDisease-Free SurvivalCarmustineTransplantation ChimeraMyeloablative AgonistsHodgkin DiseaseLeukocytes, MononuclearRetrospective StudiesBone MarrowCell SeparationSurvival AnalysisFlow CytometryBone Marrow CellsImmunosuppressive AgentsHeart TransplantationCytarabineSurvival RatePluripotent Stem CellsAntineoplastic Agents, AlkylatingMesenchymal Stem Cell TransplantationColony-Forming Units AssayLung TransplantationLeukemiaBlood Transfusion, AutologousFetal BloodAntigens, CDFollow-Up StudiesStem Cell NicheImmunomagnetic SeparationVincristineT-LymphocytesLymphomaNeural Stem CellsTransplantation, IsogeneicInduced Pluripotent Stem CellsHistocompatibility TestingTransplantation ImmunologyHistocompatibilityLeukemia, Myeloid, AcuteStem Cell FactorGraft vs Tumor EffectCell Culture TechniquesFeasibility StudiesOrgan TransplantationThiotepaNeoplasm, ResidualMesenchymal Stromal CellsMultipotent Stem CellsGraft RejectionLymphocytesCell LineageRecombinant ProteinsMyelodysplastic SyndromesImmunophenotypingPrognosisAntibodies, MonoclonalLeukocyte Count
Multiple myelomaMarrowChemotherapy followed by autologousHigh-doseLymphomaUmbilical cordHSCTMobilizationAllogeneic Hematopoietic Stem-CTherapy and autologousTransplants2023LymphoproliferativeTumorProgenitor cellsMalignantLymphocytesSignificantlyHSCsRestoresPediatricMyelomaHematopoietic stem cell mobiRemissionDifferentiationCytokinesDonorAutoimmune diseasesSurvivalUnderwentMorbidity and mortaImmuneRelapseRecipientsOutcomesCardiacTreatmentRituximabCyclophosphamideTransplant Cell Ther2021PhaseClinical1988ImmunotherapyHematologyCONCLUSIONSPatient'sTransfusionsPatientInfectionsGranulocyte
Multiple myeloma9
Marrow40
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Bone marrow transplantation , 37 (10), 929-935. (elsevierpure.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • 2 HSCs are primarily found in bone marrow niches, but a small fraction of HSCs can also be found in the peripheral blood. (bdbiosciences.com)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • These include bone marrow-derived cells, peripheral blood derived stem cells and skeletal myoblasts (3). (escardio.org)
  • In experimental and clinical studies unselected mononuclear bone marrow cells as well as specific subpopulations have been used for transplantation. (escardio.org)
  • Interestingly, contradictory data exist for transformation of bone marrow derived progenitor cells (BMPC) into new cardiomyocytes and alternative mechanisms as enhanced neovascularization, enhanced scar tissue formation due to augmented inflammatory response and decreased apoptosis have been suggested for the benefical effects of these cells on myocardial function after myocardial infarction (4). (escardio.org)
  • Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (stembook.org)
  • Biol Blood Marrow Transplant. (stembook.org)
  • Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. (stembook.org)
  • Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. (stembook.org)
  • Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. (stembook.org)
  • In autologous stem cell transplantation, stem cells are collected (or "harvested") from either the bone marrow , bloodstream (called a peripheral blood stem cell harvest), or sometimes a combination of both. (leukaemia.org.au)
  • It is more common these days to collect bone marrow stem cells from the bloodstream. (leukaemia.org.au)
  • Stem cells normally live in the bone marrow, but they can be encouraged to move out of the bone marrow and into the bloodstream. (leukaemia.org.au)
  • G-CSF promotes the production of stem cells in the bone marrow which then leak out into your normal blood circulation in your veins. (leukaemia.org.au)
  • Conditioning therapy is used to help destroy any leftover cancer cells in your body and to make or create a space in your bone marrow for the new stem cells to grow. (leukaemia.org.au)
  • From here the stem cells make their way to your bone marrow where they become re-established and start making new blood cells. (leukaemia.org.au)
  • In patients treated with Plerixafor in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. (fresenius-kabi.com)
  • For example, neutropenia or autologous bone marrow transplantation (BMT) have less adverse prognostic implications than two decades ago. (springeropen.com)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Bone marrow contains stem cells, which are immature cells that become blood cells. (medlineplus.gov)
  • People with life-threatening cancers, such as leukemia , lymphoma , and myeloma can be treated with a bone marrow transplant or, sometimes, a stem cell transplant. (medlineplus.gov)
  • Bone marrow donation can be done either by collecting a donor's bone marrow surgically, or by removing stem cells from a donor's blood. (medlineplus.gov)
  • Autologous bone marrow transplant is when people donate their own bone marrow. (medlineplus.gov)
  • First, the donor is given 5 days of shots to help stem cells move from the bone marrow into the blood. (medlineplus.gov)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
Chemotherapy followed by autologous2
High-dose9
Lymphoma16
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy. (karger.com)
  • Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (karger.com)
  • de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. (karger.com)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • This department provides medical care for patients with blood disorders, including anemia and thrombocytopenia, and neoplastic disorders such as leukemia and malignant lymphoma. (japanhospitalsearch.org)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
Umbilical cord2
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
HSCT11
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • Stem cells : HSCT for systemic sclerosis - swallows and summers. (unibas.ch)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Mobilization5
Allogeneic Hematopoietic Stem-C3
Therapy and autologous1
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Transplants3
  • In autologous stem cell transplants, the patient is their own stem cell donor. (leukaemia.org.au)
  • Autologous transplants are used to treat a number of different blood cancers. (leukaemia.org.au)
  • He has had 2 autologous stem cell transplants, 7 years and 1 year ago. (medscape.com)
20231
  • Part of Developmental Cell , p. 450-460, 2023. (uu.se)
Lymphoproliferative7
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Blaes AH, Morrison VA: Post-transplant lymphoproliferative disorders following solid-organ transplantation. (karger.com)
  • Morovic A, Jaffe ES, Raffeld M, Schrager JA: Metachronous EBV-associated B-cell and T-cell posttransplant lymphoproliferative disorders in a heart transplant recipient. (karger.com)
  • Lundell R, Elenitoba-Johnson KS, Lim MS: T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. (karger.com)
  • Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. (karger.com)
  • Yang F, Li Y, Braylan R, Hunger SP, Yang LJ: Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. (karger.com)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
Tumor5
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (nwbio.com)
  • The effect of potential reinfusion of tumor cells has not been well-studied. (fresenius-kabi.com)
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
Progenitor cells5
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • The bone morrow contains several stem cell types including hematopoetic stem cells, endothelial progenitor cells, mesenchymal (stromal) stem cells and multipotent adult progenitor cells. (escardio.org)
  • Although there is no definitive evidence, combinations of progenitor cells seem to be more benefical than specific stem cell type for cardiac repair (3). (escardio.org)
  • Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. (uchicago.edu)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
Malignant1
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
Lymphocytes4
Significantly1
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
HSCs2
Restores1
Pediatric2
  • Detection of Mucor velutinosus in a blood culture after autologous peripheral blood stem cell transplantation: a pediatric case report. (wikipedia.org)
  • T cell PTLD is rare, particularly in pediatric patients. (karger.com)
Myeloma6
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • The transferred, expanded natural killer cells proliferated in vivo in an interleukin-2 dose-dependent fashion, persisted up to 4 weeks, were readily detectable in the human bone, inhibited myeloma growth and protected bone from myeloma-induced osteolysis. (haematologica.org)
Hematopoietic stem cell mobi1
  • Hematopoietic stem cell mobilizer binds to the CXCR4 chemokine receptor and inhibits the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha). (drugs.com)
Remission4
Differentiation4
  • Moreover, it seems that paracrine action of skeletal myoblasts facilitate neighboring cardiomyocytes to maintain their replicative potential and/or stimulate differentiation of native cardiac stem cells (8,9). (escardio.org)
  • It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. (uchicago.edu)
  • Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. (uchicago.edu)
  • In the second part of our study, combining in-situ-hybridization and immunohistochemical methods, we were able to show that there is a migration of donor cells into the central nervous system of the recipient after peripheral blood stem cell transplantation as well as a differentiation of these cells into other cell types. (uni-goettingen.de)
Cytokines1
  • In vitro , CD3 + CD8 + CD27 - CD28 - compared to CD3 + CD8 + CD27 + CD28 + CART cells displayed similar CD19 + target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-γ and TNF-α). (frontiersin.org)
Donor6
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
  • If a donor's HLAs match well with a person who needs a transplant, the donor must give a new blood sample to confirm the match. (medlineplus.gov)
  • Donor stem cells can be collected in two ways. (medlineplus.gov)
  • Most donor stem cells are collected through a process called leukapheresis. (medlineplus.gov)
  • During the collection, blood is removed from the donor through a line in a vein (IV). (medlineplus.gov)
  • The red blood cells are returned to the donor through an IV in the other arm. (medlineplus.gov)
Autoimmune diseases2
  • In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)
  • Successes and failures of stem cell transplantation in autoimmune diseases. (unibas.ch)
Survival6
  • Cell therapy is a potential new treatment for post MI patients, but the main challenges are : the necessity to preserve immune competency and to gain adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Repair of scar tissue constitutes a challenge for cardiac stem cell therapy due to lack of adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
  • Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. (uchicago.edu)
Underwent3
Morbidity and morta2
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
Immune4
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
  • Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. (nwbio.com)
  • We investigated the safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients. (northwestern.edu)
Relapse2
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
  • Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. (nwbio.com)
Recipients2
  • Gassas A , Grant R , Richardson S , Dupuis LL , Doyle J , Allen U , Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. (cdc.gov)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
Outcomes4
  • To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. (cellsurgicalnetwork.com)
  • Cell therapy is currently emerging as a potential new treatment for post MI patients with the assumption that recolonization of the areas of scarred myocardium with exogenously supplied surrogates or precursors of cardiomyocytes can restore function and ultimately affect clinical outcomes. (escardio.org)
  • Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. (stembook.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
Cardiac2
Treatment11
Rituximab1
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Cyclophosphamide2
Transplant Cell Ther1
20211
Phase4
  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (nwbio.com)
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract： PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. (cdc.gov)
Clinical5
  • Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. (cellsurgicalnetwork.com)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
  • abstract： PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
19881
Immunotherapy1
  • Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. (nwbio.com)
Hematology1
  • 8 The BD ® Stem Cell Enumeration Kit incorporates BD Trucount™ tubes to determine the absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts. (bdbiosciences.com)
CONCLUSIONS1
  • Conclusions These studies provide the rationale for testing expanded natural killer cells in humans. (haematologica.org)
Patient's3
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • They are used to replace stem cells that have been damaged by high doses of chemotherapy , used to treat the patient's underlying disease. (leukaemia.org.au)
  • Staff attempted to draw blood for work-up before a CT evaluation of the patient's lungs, but had difficulty in obtaining a specimen that the laboratory would accept. (medscape.com)
Transfusions2
  • Red blood cell transfusions are given when your haemoglobin levels are too low. (leukaemia.org.au)
  • A type and antibody screen specimen obtained before the transfusions revealed that his red cells were type B positive, a screen for unexpected antibodies was negative, and direct antibody tests (DAT) for both anti-IgG and anti-C3b were also negative. (medscape.com)
Patient2
  • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. (shengsci.com)
  • As a result of persistent hypotension, the patient was transfused with 3 units of uncrossmatched, type O red blood cells. (medscape.com)
Infections1
  • During this time you will be more at risk of infections (due to the lack of infection-fighting white blood cells ) and bleeding (due to a lack of platelets ). (leukaemia.org.au)
Granulocyte1
  • Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. (uchicago.edu)